Invitrogen's Q3 Revenues, Profit Spur 10 Percent Stock Surge | GenomeWeb
NEW YORK (GenomeWeb News) - Invitrogen’s share price jumped 10 percent today after the firm released third-quarter results that showed a double-digit increase in revenues and a swing from a loss to a profit.
 
The firm reported after the close of the market yesterday that its third-quarter revenues had spiked up 11 percent to $315 million and that last year’s losses had been turned to a $31 million profit.
 
The stock was up $8.34 at $91.41 in late afternoon trading today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.